New Trial Shows Aggressive Cholesterol Targets Reduce Major Cardiovascular Events by One Third in High Risk Patients

ACC.26 trial shows that targeting LDL cholesterol below 55 mg/dL significantly reduces heart attacks and strokes in patients with atherosclerotic disease.

By: AXL Media

Published: Mar 30, 2026, 4:11 AM EDT

Source: Information for this report was sourced from American College of Cardiology

Validating Intensive Lipid Management for Atherosclerotic Disease

A significant gap in clinical evidence has been addressed by a new head-to-head trial comparing two major cholesterol treatment targets. According to Byeong-Keuk Kim, a professor at the Yonsei University College of Medicine, targeting a low-density lipoprotein (LDL) level of less than 55 mg/dL provides a superior level of protection for patients already suffering from heart disease. While international guidelines have recently moved toward recommending these more aggressive numbers, the Ez-PAVE trial provides the first randomized, practical evidence that hitting the lower target results in a 33% reduction in major cardiovascular events. This confirms that for patients with established plaque buildup, "lower is better" remains the primary directive for preventing future cardiac crises.

The Mechanics of Plaque Stabilization and LDL Reduction

Atherosclerotic cardiovascular disease, or ASCVD, is characterized by the accumulation of fatty deposits within the arterial walls, a process heavily fueled by LDL cholesterol. When these plaques become unstable, they can rupture, leading to the sudden formation of blood clots that cause heart attacks or strokes. By aggressively lowering LDL levels, clinicians can not only slow the growth of new deposits but also help stabilize existing plaques, making them less likely to trigger a fatal event. The trial demonstrated that achieving these intensive targets often requires a combination of high-intensity statins and non-statin therapies, such as ezetimibe or PCSK9 inhibitors, to effectively clear the bloodstream of harmful lipids.

Analyzing Clinical Outcomes and Risk Reduction in Ez-PAVE

The study followed 3,048 high-risk patients in South Korea over a three-year period to measure the impact of the two different treatment goals. In the group assigned the more aggressive 55 mg/dL target, the composite rate of cardiovascular death, heart attack, and stroke was 6.6%, compared to 9.7% in the group following the conventional 70 mg/dL target. This marked difference was primarily driven by a significant decrease in nonfatal heart attacks and the need for emergency procedures to reopen blocked arteries. Notably, the most intensive group saw their risk of the most severe outcomes—death, heart attack, or stroke—drop to 2.3%, compared to 3.6% in the standard care gro...